Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00005018 · ClinicalTrials.gov registry record · Phase 4
Safety and Effectiveness of a Combination Anti-HIV Drug Treatment
A Phase 4 study, sponsored by Glaxo Wellcome.
- Completed
- Registry status
- Phase 4
- Development phase
- 150
- Enrollment target
NCT00005018 is a Phase 4 study that has completed, run by Glaxo Wellcome. The registered enrollment target is 150 participants.
The verdict
NCT00005018, a Phase 4 study, has completed, sponsored by Glaxo Wellcome.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 150 participants
- Enrollment target
Study Summary
The purpose of this study is to see if it is safe and effective to give HIV-positive patients a combination of anti-HIV drugs (abacavir \[ABC\] plus efavirenz \[EFV\] plus didanosine \[ddI\]) with and without hydroxyurea (HU).
Interventions
- DRUG Hydroxyurea
- DRUG Efavirenz
- DRUG Didanosine
- DRUG Abacavir sulfate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 1999-07 |
| Est. Completion | 2000-10 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00005018
The ClinicalTrials.gov registry entry for NCT00005018 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Glaxo Wellcome, which has 65 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Hydroxyurea is the first listed.
NCT00005018 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00005018 about?
NCT00005018 is a clinical study titled "Safety and Effectiveness of a Combination Anti-HIV Drug Treatment". The purpose of this study is to see if it is safe and effective to give HIV-positive patients a combination of anti-HIV drugs (abacavir \[ABC\] plus efavirenz \[EFV\] plus didanosine \[ddI\]) with and without hydroxyurea (HU).
What is the current status of trial NCT00005018?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 150 participants. The study started on 1999-07. Estimated completion is 2000-10.
What interventions are being tested in trial NCT00005018?
The interventions under investigation include: Hydroxyurea (DRUG), Efavirenz (DRUG), Didanosine (DRUG), Abacavir sulfate (DRUG).
Who is sponsoring clinical trial NCT00005018?
This trial is sponsored by Glaxo Wellcome, which has 65 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.